Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Protara Therapeutics ( (TARA) ) has issued an update.
On November 19, 2025, Protara Therapeutics announced interim results from its Phase 2 STARBORN-1 clinical trial of TARA-002 for pediatric patients with lymphatic malformations. The data indicated that the majority of evaluable patients achieved clinical success, with no serious adverse events reported. This development highlights the potential of TARA-002 to address a significant unmet need in treating macrocystic and mixed-cystic LMs, potentially positioning Protara as a leader in this rare disease market.
The most recent analyst rating on (TARA) stock is a Buy with a $26.00 price target. To see the full list of analyst forecasts on Protara Therapeutics stock, see the TARA Stock Forecast page.
Spark’s Take on TARA Stock
According to Spark, TipRanks’ AI Analyst, TARA is a Underperform.
Protara Therapeutics faces considerable challenges typical in early-stage biotech, such as no revenue and persistent cash outflows. However, the strong equity and low debt levels provide some stability. The recent positive trial results are promising, but the stock remains high-risk due to its financial and operational metrics.
To see Spark’s full report on TARA stock, click here.
More about Protara Therapeutics
Protara Therapeutics is a biopharmaceutical company focused on developing treatments for rare diseases and oncology. Their primary product, TARA-002, is an investigational cell-based therapy aimed at treating lymphatic malformations (LMs) in pediatric patients.
Average Trading Volume: 485,365
Technical Sentiment Signal: Buy
Current Market Cap: $214.9M
For a thorough assessment of TARA stock, go to TipRanks’ Stock Analysis page.